BioCryst Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $263.9M | $-88.9M | $-226.5M | $-247.1M | $-184.1M | $-182.8M | $-108.9M | $-101.3M |
| Depreciation & Amortization | $1.4M | $1.2M | $1.7M | $1.4M | $777.0K | $748.0K | $724.0K | $770.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $85.1M | $65.4M | $55.6M | $44.7M | $34.6M | $14.8M | $17.7M | $9.4M |
| Net Cash from Operating Activities | $347.4M | $-52.0M | $-95.1M | $-161.9M | $-142.2M | $-135.1M | $-89.6M | $-92.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.5M | $1.1M | $2.2M | $1.4M | $2.4M | $514.0K | $343.0K | $366.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-13.7M | $52.6M | $-131.5M | $-128.2M | $15.8M | $-6.9M | $77.9M | $4.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-349.9M | $-5.8M | $32.5M | $88.0M | $359.7M | $300.6M | $99.1M | $62.5M |
| Net Change in Cash | $-15.0M | $-6.1M | $-193.8M | $-201.5M | $233.4M | $158.6M | $87.4M | $-25.3M |
| Free Cash Flow | $344.9M | $-53.1M | $-97.3M | $-163.2M | $-144.5M | $-135.6M | $-89.9M | $-92.9M |